Background
Walled-off necrosis (WON) is a type of pancreatic fluid collection (PFC) that develops in the setting of acute or chronic pancreatitis, trauma, or pancreatic duct obstruction [
1]. WON, a delayed complication of necrotizing pancreatitis usually occurring > 4 weeks following the onset of pancreatitis, is PFC surrounded by a radiologically identifiable capsule containing both solid and liquid components [
1]. Most WONs are asymptomatic and resolve spontaneously. However, drainage is necessary when it becomes symptomatic or infected, or increases in size over the course of the illness.
In the past decade, the treatment of symptomatic WON has evolved from surgical to endoscopic necrosectomy. Endoscopic treatment has a reduced proinflammatory response compared to surgery for the treatment of WONs [
2]. It is associated with lower rates of pancreatic fistula formation and shorter hospital stays [
3,
4]. Endoscopic ultrasonography (EUS)-guided drainage has high technical and clinical success and is associated with low adverse events (AEs) making it the optimal drainage approach for WONs [
5,
6].
Double pigtail plastic stents (DPPS) is the standard choice for pancreatic pseudocyst drainage with > 90% technical and clinical success rates [
5]. DPPS has also been used for WON drainage [
7]. Recently, a novel lumen-apposing metal stent (LAMS) with a larger luminal diameter (≥ 10 mm) has been successfully used for EUS-guided drainage of PFC [
8]. A multi-institutional consensus made by 22 expert endosonographers recommended that LAMS should be the standard of care for WON drainage [
9].
However, the safety of LAMS is still controversial. Some studies have reported that LAMS is superior to DPPS in terms of overall treatment efficacy (90% vs 81%) and a significantly lower number of procedures (2.2 vs 3.6) [
10]. LAMS includes single-step deployment and has an anti-migration structure [
11,
12]. Other studies have proposed that LAMS was associated with a significantly higher rate of bleeding compared with DPPS [
13‐
15]. Moreover, high quality of evidence with regards to the efficacy and safety of LAMS for WON drainage in Chinese patients is lacking. Given the recent widespread use of LAMS in the management of WON, we designed this open-label, prospective, parallel-group, superiority, multi-center randomized controlled trial (RCT) to investigate whether LAMS is superior to DPPS for WON drainage.
Discussion
The LVPWON trial has been designed to answer the question of whether LAMS is superior to DPPS for EUS-guided drainage of WON with regards to the clinical success rate and the incidence of AEs. We also want to prospectively investigate the risk factors for success of treatment and complications of EUS-guided drainage, which will provide a reference for the clinical treatment of WON.
EUS-guided drainage has been maturely applied in late PFC with well-defined inflammatory walls [
7,
16‐
18]. Stents used for drainage are diverse. DPPS used in the management of PFC was first reported in the 1980s [
19]. Subsequently, self-expanding metal stents (SEMS) and double-flanged LAMS have become the most popular drainage stents for PFC [
8,
11,
12].
Due to their small diameter, several DPPSs are needed to achieve adequate drainage of a WON. Metal stents that have a larger diameter are theoretically considered superior to DPPS as they allow for the possibility of WON debridement. A previous study directly comparing DPPS and LAMS demonstrated that the latter had a success rate of 90%, which was higher than the former, and a significantly fewer number of procedures were required with LAMS for WON resolution [
10]. In terms of AEs, stent occlusion seems more likely to occur in WON treated with DPPS [
10]. Furthermore, new technology associated with LAMS enhance the drainage effect [
20]. The procedure of LAMS deployment has become much easier and more economical.
However, with the increasing use of LAMS for WON drainage, LAMS-related bleeding has been more frequently reported [
13‐
15]. In combined endoscopic and percutaneous drainage for symptomatic WON, LAMS did not reduce the time to percutaneous drain removal and was not associated with fewer AEs [
21]. Furthermore, LAMS is substantially more expensive than DPPS.
Recently, a consensus guideline formulated by the Asian EUS group RAND/UCLA expert panel raised the issue of stent selection [
5]. There are currently no randomized data addressing how LAMS compare with DPPS for WON drainage. An ongoing RCT observed serious LAMS-related AEs, including delayed bleeding in 50% of patients (6/12), buried stent syndrome, and biliary stricture [
14]. However, our team had analyzed our center’s experience and determined that the use of LAMS is safe [
22].
The LVPWON trial was initiated by Changhai Hospital, which is a National Clinical Research Center for Digestive Diseases. This is the largest prospective, open-label, parallel-group, superiority, multi-center RCT to address the appropriate selection of the stent for WON drainage. The trial includes 18 Chinese tertiary hospitals. Despite discrepancies in diagnostic and operational skill levels at different centers, as the research initiator, Changhai Hospital will provide technical training. Only experienced endosonographers will perform drainage procedures. The trial will also adopt “centralized readings” to reduce the heterogeneity between centers. Given the differences in the type of stent that will be placed, endoscopists and patients will not be blinded to the treatment allocation. However, the outcomes of the trial are unlikely to be affected by the patient’s psychological factors.
In conclusion, the major focus of the LVPWON trial is to prospectively compare the efficacy and safety of LAMS and DPPS in EUS-guided drainage of WON and to identify the risk factors associated with LAMS-related complications, thus further benefiting WON patients treated with LAMS.
Trial status
This multicenter RCT is expected to begin enrolling patients on 30 September 2018. Protocol version number: V 2.0, 2017-10-10. The approximate date when recruitment will be completed is 30 September 2019.